Galinpepimut-S

Summary

Galinpepimut-S (CHEMBL3833386) is a phase-3 clinical-stage unknown; indicated across 1 condition including acute myeloid leukemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833386
Name	Galinpepimut-S
Type	Unknown
Max phase	3

Also known as: Galinpepimut-s, SLS-001, GALINPEPIMUT-S

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acute myeloid leukemia	3	MONDO:0018874	EFO:0000222

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1/PHASE2	2
PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04229979	PHASE3	ACTIVE_NOT_RECRUITING	Galinpepimut-S Versus Investigator’s Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT01265433	PHASE2	COMPLETED	Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
NCT01266083	PHASE2	COMPLETED	WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
NCT01827137	PHASE1/PHASE2	COMPLETED	WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
NCT03761914	PHASE1/PHASE2	COMPLETED	Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
NCT04040231	PHASE1	COMPLETED	Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
NCT05593185	Not specified	AVAILABLE	Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).